Browsing by Author "Dimopoulos, M. A."
Now showing items 1-20 of 38
-
Article
Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience
Pectasides, Dimitrios; Fountzilas, George; Aravantinos, Gerasimos; Kalofonos, H. P.; Efstathiou, E.; Farmakis, D.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Economopoulos, T.; Dimopoulos, M. A. (2006)Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study ...
-
Article
Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: The Hellenic Cooperative Oncology Group experience
Pectasides, Dimitrios; Economopoulos, T.; Kouvatseas, G.; Antoniou, A.; Zoumbos, Z.; Aravantinos, Gerasimos; Tsatalas, C.; Halikia, A.; Nikolaides, C.; Kiamouris, Ch; Pappa, E.; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Fountzilas, George; Dimopoulos, M. A. (2000)Testicular non-Hodgkin's lymphoma is an uncommon disease and its outcome following chemotherapy and/or radiotherapy has been variable. A retrospective analysis was performed on 26 patients with primary testicular lymphoma ...
-
Article
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: A Hellenic Cooperative Oncology Group study
Nikitas, N.; Karadimou, A.; Tsitoura, E.; Soupos, N.; Tsiatas, M.; Karavasilis, V.; Pectasides, Dimitrios; Pavlidis, Nicholas; Chrisofos, M.; Adamakis, I.; Murray, S.; Fountzilas, George; Dimopoulos, M. A.; Bamias, A. T. (2012)Aim: The association between two polymorphisms of ERCC1 and treatment outcomes after platinum-based chemotherapy in patients with advanced urothelial cancer (UC) was examined. Materials & methods: Genotyping of 19007C>T ...
-
Article
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature
Pectasides, Dimitrios; Aravantinos, Gerasimos; Fountzilas, George; Kalofonos, H. P.; Efstathiou, E.; Karina, M.; Pavlidis, Nicholas; Farmakis, D.; Economopoulos, T.; Dimopoulos, M. A. (2005)Background: Brain metastases from epithelial ovarian cancer (EOC) are rare. A retrospective study of all patients diagnosed with brain metastases from EOC over the last 20 years, according to the Hellenic Cooperative ...
-
Article
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...
-
Article
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group
Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...
-
Article
Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study
Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...
-
Article
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results
Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...
-
Article
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group
Skarlos, Dimosthenis V.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Papakostas, P.; Pavlidis, Nicholas; Bacoyiannis, Charalambos; Kiamouris, Ch; Klouvas, G. D.; Gogas, H.; Fountzilas, George; Samantas, E. (2003)There is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part ...
-
Article
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...
-
Article
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
Fountzilas, George; Papadimitriou, C.; Aravantinos, Gerasimos; Nikolaides, C.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Economopoulos, T.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Dose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer
Razi, E. D.; Dimopoulos, M. A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Briassoulis, E. Ch; Samantas, E.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Fountzilas, George (2001)The purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group
Fountzilas, George; Papadimitriou, C.; Dafni, U.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Moulopoulos, L. A.; Razi, E. D.; Kalofonos, H. P.; Aravantinos, Gerasimos; Briassoulis, E. Ch; Papakostas, P.; Abela, K.; Gogas, H.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, ...
-
Article
Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG)
Pectasides, Dimitrios; Papaxoinis, G.; Fountzilas, George; Aravantinos, Gerasimos; Bamias, A. T.; Pavlidis, Nicholas; Kalofonos, H. P.; Timotheadou, E.; Samantas, E.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Economopoulos, T.; Dimopoulos, M. A. (2009)Background: The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC). Patients and Methods: ...
-
Article
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
-
Article
Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: A hellenic cooperative oncology group study
Dimopoulos, M. A.; Papadopoulou, M.; Andreopoulou, E.; Papadimitriou, C.; Pavlidis, Nicholas; Aravantinos, Gerasimos; Aspropotamitis, A.; Anagnostopoulos, A.; Fountzilas, George; Michalas, S.; Pectasides, Dimitrios (1998)Purpose. To evaluate the outcome and the prognosis of patients with ovarian germ cell malignancies who were treated with platinum-based chemotherapy immediately after initial surgery. Methods. We conducted a retrospective ...
-
Article
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Dimopoulos, M. A.; Papadimitriou, C.; Kalogera-Fountzila, Anna; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Athanasiades, A.; Nikolaides, C.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1998)Purpose: To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first- line chemotherapy in patients with advanced breast cancer (ABC). Background: Paclitaxel ...
-
Article
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting
Briassoulis, E. Ch; Andreopoulou, E.; Ch, F. Tolis; Bairaktari, Eleni Th; Katsaraki, A.; Dimopoulos, M. A.; Fountzilas, George; Seferiadis, C.; Pavlidis, Nicholas (2001)BACKGROUND. Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS. ...
-
Article
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group
Nikolaides, C.; Dimopoulos, M. A.; Samantas, E.; Bafaloukos, Dimitrios; Kalofonos, H. P.; Fountzilas, George; Razi, E. D.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)Background: Gemcitabine and vinorelbine have shown activity in breast cancer. A phase II trial was initiated in order to evaluate the response rate (RR) and time to progression (TTP) of the combination of the two drugs in ...
-
Article
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
Skarlos, Dimosthenis V.; Kalofonos, H. P.; Fountzilas, George; Dimopoulos, M. A.; Pavlidis, Nicholas; Razi, E. D.; Economopoulos, T.; Pectasides, Dimitrios; Gogas, H.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Klouvas, G. D.; Kyratzis, G.; Aravantinos, Gerasimos (2005)Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory ...